156 related articles for article (PubMed ID: 34478124)
1. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
3. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
[TBL] [Abstract][Full Text] [Related]
4. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
5. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
[TBL] [Abstract][Full Text] [Related]
6. Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis.
Mirsaeidi M; Baughman RP; Sahoo D; Tarau E
Pulm Ther; 2023 Jun; 9(2):237-253. PubMed ID: 37072607
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM
Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199
[TBL] [Abstract][Full Text] [Related]
8. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.
Furie RA; Mitrane M; Zhao E; Becker PM
Lupus Sci Med; 2017; 4(1):e000240. PubMed ID: 29344387
[TBL] [Abstract][Full Text] [Related]
9. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
Askanase AD; Furie RA
Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
Burge DJ; Werth VP; Boackle SA; Posada J
Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
[TBL] [Abstract][Full Text] [Related]
11. Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio M; Karlsson D; Furst DE
Rheumatol Ther; 2022 Apr; 9(2):649-661. PubMed ID: 35184268
[TBL] [Abstract][Full Text] [Related]
12. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus.
Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
Adv Ther; 2023 Jan; 40(1):194-210. PubMed ID: 36266383
[TBL] [Abstract][Full Text] [Related]
14. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
15. Repository Corticotropin Injection (Acthar
Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
[TBL] [Abstract][Full Text] [Related]
16. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA; Bruce IN; Dörner T; Leon MG; Leszczyński P; Urowitz M; Haier B; Jimenez T; Brittain C; Liu J; Barbey C; Stach C
Rheumatology (Oxford); 2021 Nov; 60(11):5397-5407. PubMed ID: 33956056
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Philbin M; Niewoehner J; Wan GJ
Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
[TBL] [Abstract][Full Text] [Related]
19. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
Furie R; Morand EF; Bruce IN; Isenberg D; van Vollenhoven R; Abreu G; Pineda L; Tummala R
Arthritis Rheumatol; 2021 Nov; 73(11):2059-2068. PubMed ID: 33913260
[TBL] [Abstract][Full Text] [Related]
20. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
